Trump said you could learn something from this man

Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement.

Carl Feldbaum Biography and Net Worth

Director of Exelixis

Carl B. Feldbaum Esq., J.D. serves as Independent Director of the Company. Carl B. Feldbaum, Esq., has been a director since February 2007. Mr. Feldbaum serves as a member emeritus of the board of directors of BIO Ventures for Global Health, a non-profit organization, and is president emeritus of the Biotechnology Innovation Organization (BIO), which is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. Mr. Feldbaum served as president of BIO from 1993 until his retirement in 2005. Prior to joining BIO, Mr. Feldbaum was chief of staff to Senator Arlen Specter of Pennsylvania. He also was president and founder of Palomar Corporation, a national security “think tank” in Washington, D.C. Before founding Palomar Corporation, Mr. Feldbaum was Assistant to the Secretary of Energy and served as the Inspector General for defense intelligence in the U.S. Department of Defense. Mr. Feldbaum served as a member of the board of directors of the following publicly held companies: Actelion, Ltd, a biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs (acquired by Johnson & Johnson in 2017), from 2005 to 2015; Trovagene, Inc., a precision medicine biotechnology company focused on the development of oncology therapeutics for improved cancer care, from 2014 to 2015; and Connetics Corporation, a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics for the dermatology market, from 2005 until its acquisition by Stiefel Laboratories, Inc. in 2006. Mr. Feldbaum holds an A.B. in Biology from Princeton University and a J.D. from the University of Pennsylvania Law School.

What is Carl B. Feldbaum's net worth?: The estimated net worth of Carl B. Feldbaum is at least $647,989.65 as of February 9th, 2023. Mr. Feldbaum owns 18,701 shares of Exelixis stock worth more than $647,990 as of November 21st. This net worth estimate does not reflect any other investments that Mr. Feldbaum may own. Learn More about Carl B. Feldbaum's net worth.
How do I contact Carl B. Feldbaum?: The corporate mailing address for Mr. Feldbaum and other Exelixis executives is 1851 Harbor Bay Parkway, Alameda CA, 94502. Exelixis can also be reached via phone at (650) 837-7000 and via email at [email protected]. Learn More on Carl B. Feldbaum's contact information.
Has Carl B. Feldbaum been buying or selling shares of Exelixis?: Carl B. Feldbaum has not been actively trading shares of Exelixis during the past quarter. Most recently, Carl B. Feldbaum sold 40,000 shares of the business's stock in a transaction on Thursday, February 9th. The shares were sold at an average price of $17.78, for a transaction totalling $711,200.00. Following the completion of the sale, the director now directly owns 18,701 shares of the company's stock, valued at $332,503.78. Learn More on Carl B. Feldbaum's trading history.
Who are Exelixis' active insiders?: Exelixis' insider roster includes Dana Aftab (EVP), Charles Cohen (Director), Carl Feldbaum (Director), Maria Freire (Director), Maria Freire (Director), Alan Garber (Director), Patrick Haley (EVP), Jeffrey Hessekiel (EVP), David Johnson (Director), Peter Lamb (EVP), Vincent Marchesi (Director), Michael Morrissey (CEO), Stelios Papadopoulos (Director), George Poste (Director), Gisela Schwab (CMO), Christopher Senner (CFO), Lance Willsey (Director), and Jack Wyszomierski (Director). Learn More on Exelixis' active insiders.
Are insiders buying or selling shares of Exelixis?: In the last year, Exelixis insiders bought shares 4 times. They purchased a total of 735,409 shares worth more than $15,270,038.49. In the last year, insiders at the biotechnology company sold shares 22 times. They sold a total of 783,864 shares worth more than $21,654,310.33. The most recent insider tranaction occured on November, 18th when EVP Patrick J Haley sold 41,588 shares worth more than $1,428,963.68. Insiders at Exelixis own 2.9% of the company. Learn More about insider trades at Exelixis.
Information on this page was last updated on 11/18/2024.

Carl B. Feldbaum Insider Trading History at Exelixis

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/9/2023	Sell	40,000	$17.78	$711,200.00	18,701
11/19/2021	Sell	20,000	$17.62	$352,400.00
2/16/2021	Sell	20,000	$21.96	$439,200.00	28,521
3/3/2020	Sell	38,000	$18.84	$715,920.00	40,521
2/14/2019	Sell	50,500	$22.03	$1,112,515.00	30,221
5/30/2018	Sell	34,262	$20.60	$705,797.20	45,983
5/15/2017	Sell	32,988	$21.58	$711,881.04	52,721
12/16/2016	Sell	25,000	$17.03	$425,750.00

Carl B. Feldbaum Buying and Selling Activity at Exelixis

Exelixis Company Overview

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Today's Range

Now: $34.65

$34.25

$34.81

50 Day Range

MA: $29.55

$25.39

$36.25

2 Week Range

Now: $34.65

$19.20

$36.60

Volume

1,758,812 shs

Average Volume

2,572,711 shs

Market Capitalization

$9.90 billion

P/E Ratio

22.21

Dividend Yield

N/A

Beta

0.51

Trump said you could learn something from this man

From Wide Moat Research | Ad

Here’s everything you need to know.